When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KOD - Kodiak Sciences lead drug continues to show benefit in early-stage study in eye disorders
Kodiak Sciences Inc
Kodiak Sciences (NASDAQ:KOD) announces updated data from a Phase 1b clinical trial evaluating lead candidate in KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). The results were presented virtually at the American Society of Retina Specialists Annual Meeting.
More news on: Kodiak Sciences Inc., Healthcare stocks news,